Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (NCT05776225) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United States300 participantsStarted 2023-08-11
Plain-language summary
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient gives voluntary written informed consent to participate in the study and are capable of reading and understanding questionnaires or forms in English or Spanish.
✓. Patients with a diagnosis of ILD based on computed tomography imaging, including:
✓. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis
. History of ischemic heart disease or left-sided myocardial dysfunction within 12 months of Screening, defined as left ventricular ejection fraction \<40% or pulmonary capillary wedge pressure \>15 mmHg.
✕. Any other clinical features that, in the opinion of the Investigator, might adversely affect interpretation of study data or study safety, or make the patient unsuitable for RHC or HRCT (e.g., pregnancy).